期刊
EXPERT OPINION ON DRUG DELIVERY
卷 19, 期 6, 页码 685-705出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2022.2083106
关键词
Liposomes; drug delivery; active targeting; receptor-mediated endocytosis; transferrin
资金
- 'Faculty of Pharmacy' of Tabriz University of Medical Sciences
- 'Drug Applied Research Center' of Tabriz University of Medical Sciences
TfR serves as a valuable target for cancer therapy, with potential for TfR-targeted liposomes as promising drug delivery vehicles. Despite the attention gained, the full assessment of TfR ligands applied for liposomal targeted delivery still needs to be accomplished.
Introduction Compared to normal cells, malignant cancer cells require more iron for their growth and rapid proliferation, which can be supplied by a high expression level of transferrin receptor (TfR). It is well known that the expression of TfR on the tumor cells is considerably higher than that of normal cells, which makes TfR an attractive target in cancer therapy. Areas covered In this review, the primary focus is on the role of TfR as a valuable tool for cancer-targeted drug delivery, followed by the full coverage of available TfR ligands and their conjugation chemistry to the surface of liposomes. Finally, the most recent studies investigating the potential of TfR-targeted liposomes as promising drug delivery vehicles to different cancer cells are highlighted with emphasis on their improvement possibilities to become a part of future cancer medicines. Expert opinion Liposomes as a valuable class of nanocarriers have gained much attention toward cancer therapy. From all the studies that have exploited the therapeutic and diagnostic potential of TfR on cancer cells, it can be realized that the systematic assessment of TfR ligands applied for liposomal targeted delivery has yet to be entirely accomplished.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据